Please see new guidance from the UK Chemotherapy Board on ‘Personalised Medicine Approach For Fluoropyrimidine-based Therapies’.
Objective of document: To provide clinical staff with guidance as to which patients should receive a DPD test and then subsequently to provide advice to clinical staff on the outcome of that test.
Full guidance can be accessed HERE or found in our resource center in the BOPA website.
Abstract Submission for the 27th Annual BOPA Conference in 2024 is now OPEN Delegates are invited to present results of their clinical and technical work as a poster with…
We invite members to complete this service evaluation to understand national variations in carboplatin dosing for adult patients receiving SACTs. We are looking at whether we can standardise carboplatin protocols…
Thursday 25th April 2024 1-2pm BST Register for the Session HERE: https://www.bopa.org.uk/webinarsignupform/ We would like to invite you to join our ‘My Research’ sessions. These sessions are delivered…
BOPA is proud to be part of the UK PPL Board and represent all Pharmacy Professionals and Cancer Pharmacy Professionals across the UK. For more information see the letter on…
The 27th BOPA Annual Conference in 2024 will be held at the ICC Birmingham on 11-13 October.
Check out the latest information here: https://www.bopa.org.uk/latest-Conference-2024/
Everything you need to know
